Precision paradigm in breast cancer management: A mini review

IF 0.3 Q4 OBSTETRICS & GYNECOLOGY

Revista de Senologia y Patologia Mamaria Pub Date : 2025-05-29 DOI:10.1016/j.senol.2025.100703

Suman Bhadra , Sohini Kulavi , Jaya Bandyopadhyay

{"title":"Precision paradigm in breast cancer management: A mini review","authors":"Suman Bhadra , Sohini Kulavi , Jaya Bandyopadhyay","doi":"10.1016/j.senol.2025.100703","DOIUrl":null,"url":null,"abstract":"<div><div>“One-size-fits-all” is a conventional medical approach to treating patients with similar symptoms with similar types of drugs. The effectiveness of various targeted therapies in such diverse tumors has entered an era in which treatment is determined based on the tumor's molecular abnormality profile, or “characteristics,” rather than on the type of tumor tissue or the site of anatomical origin. It improves the prognosis of patients and determines their quality of life. The evolving field of personalized medicinal drugs has significant potential in cancer prevention, diagnosis, and therapeutics. Identifying cancer susceptibility genes, such as the BRCA gene in breast cancer, helps screening programs identify patients at risk for developing cancer and make decisions about individual risk-modifying behaviors. Precision medicine plays a vital role in breast cancer management, e.g., using intracellular agents (Vemurafenib and Olaparib) and monoclonal antibodies (Cetuximab and Trastuzumab) in HER2-positive breast cancer. This review mainly focuses on the role of precision medicine in preventing and treating breast cancer.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 3","pages":"Article 100703"},"PeriodicalIF":0.3000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158225000398","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

“One-size-fits-all” is a conventional medical approach to treating patients with similar symptoms with similar types of drugs. The effectiveness of various targeted therapies in such diverse tumors has entered an era in which treatment is determined based on the tumor's molecular abnormality profile, or “characteristics,” rather than on the type of tumor tissue or the site of anatomical origin. It improves the prognosis of patients and determines their quality of life. The evolving field of personalized medicinal drugs has significant potential in cancer prevention, diagnosis, and therapeutics. Identifying cancer susceptibility genes, such as the BRCA gene in breast cancer, helps screening programs identify patients at risk for developing cancer and make decisions about individual risk-modifying behaviors. Precision medicine plays a vital role in breast cancer management, e.g., using intracellular agents (Vemurafenib and Olaparib) and monoclonal antibodies (Cetuximab and Trastuzumab) in HER2-positive breast cancer. This review mainly focuses on the role of precision medicine in preventing and treating breast cancer.

查看原文本刊更多论文

乳腺癌管理的精确范式：一个小回顾

“一刀切”是一种传统的医学方法，用类似类型的药物治疗症状相似的患者。各种靶向治疗在这种不同肿瘤中的有效性已经进入了一个根据肿瘤的分子异常特征或“特征”来确定治疗的时代，而不是根据肿瘤组织的类型或解剖起源的位置。它改善了患者的预后，决定了患者的生活质量。不断发展的个体化药物在癌症预防、诊断和治疗方面具有巨大的潜力。确定癌症易感基因，如乳腺癌中的BRCA基因，有助于筛查项目确定有患癌症风险的患者，并对个人风险调整行为做出决定。精准医学在乳腺癌管理中发挥着至关重要的作用，例如，在her2阳性乳腺癌中使用细胞内药物（Vemurafenib和Olaparib）和单克隆抗体（西妥昔单抗和曲妥珠单抗）。本文主要就精准医学在乳腺癌防治中的作用进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊